Skip to main content
SpringerLink
Log in

Cervical Cytology Biobanks as a Resource for Molecular Epidemiology

  • Protocol
  • First Online:
Methods in Biobanking

Part of the book series: Methods in Molecular Biology ((MIMB,volume 675))

Abstract

A cervical cytology biobank (CCB) is an extension of current cytopathology laboratory practice consisting in the systematic storage of Pap smears or liquid-based cytology samples from women participating in cervical cancer screening with the explicit purpose of facilitating future scientific research and quality audit of preventive services. A CCB should use an internationally agreed uniform cytology terminology, be integrated in a national or regional screening registry, and linked to other registries (histology, cancer, and vaccination). Legal and ethical principles concerning personal integrity and data safety must be respected strictly. Biobank-based studies require approval from ethical review boards.

A CCB constitutes a nearly inexhaustible resource to perform fundamental and applied biologic research. In particular, it can contribute in answering questions on the natural history of HPV infection and HPV-induced lesions and cancers, screening effectiveness, exploration of new biomarkers, and surveillance of short- and long-term effects of the introduction of HPV vaccination.

To understand the limitations of CCB, more studies are needed on quality of samples in relation to sample type, storage procedures, and duration of storage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Council of the European Union (2003) Council Recommendation of 2 December 2003 on Cancer Screening. Off. J. Eur. Union 878: 34–38.

    Google Scholar 

  2. Advisory Committee on Cancer Prevention (2000) Recommendations on cancer screening in the European Union. Advisory Committee on Cancer Prevention. Eur. J. Cancer 36: 1473–1478.

    Article  Google Scholar 

  3. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening – 2nd Edition. Arbyn M., Anttila A., Jordan J., Schenck U., Ronco G., Segnan N., and Wiener H., eds. (2008), 2nd edn. Office for Official Publications of the European Communities, Luxembourg.

    Google Scholar 

  4. Wiener H.G., Klinkhamer P., Schenck U., Arbyn M., Bulten J., Bergeron C., and Herbert A. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for cytology laboratories. Cytopathology 18: 67–78.

    Article  PubMed  CAS  Google Scholar 

  5. Anttila A., Ronco G., Clifford G., Bray F., Hakama M., Arbyn M., and Weiderpass E. (2004) Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 91: 935–941.

    PubMed  CAS  Google Scholar 

  6. Linos A. and Riza E. (2000) Comparisons of cervical cancer screening programmes in the European Union. Eur. J. Cancer 36: 2260–2265.

    Article  PubMed  CAS  Google Scholar 

  7. Ballegooijen M., van Marle M.E., Patnick J., Lynge E., Arbyn M., Anttila A., Ronco G., and Habbema D.F. (2000) Overview of important cervical cancer screening process values in EU-countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur. J. Cancer 36: 2177–2188.

    Article  PubMed  Google Scholar 

  8. Arbyn M. and Dillner J. (2007) Review of current knowledge on HPV vaccination: An appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J. Clin. Virol. 38: 189–197.

    Article  PubMed  Google Scholar 

  9. Wallin K.L., Wiklund F., Angstrom T., Bergman F., Stendahl U., Wadell G., Hallmans G., and Dillner J. (1999) Type-specific persistence of human papillomavirus DNA before the development of invase cervical cancer. N. Engl. J. Med. 341: 1633–1638.

    Article  PubMed  CAS  Google Scholar 

  10. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K.E., Andersen P.K., Ponten J., Adami H.-O., Gyllensten U.B., and Melbye M. (2000) Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 355: 2194–2198.

    Article  PubMed  CAS  Google Scholar 

  11. Ylitalo N., Josefsson A., Melbye M., Sorensen P., Frisch M., Andersen P.K., Sparen P., Gustafsson M., Magnusson P., Ponten J., Gyllensten U., and Adami H.O. (2000) A prospective study showing long-term infection with human ­papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 60: 6027–6032.

    PubMed  CAS  Google Scholar 

  12. Zielinski G.D., Snijders P.J., Rozendaal L., Voorhorst F.J., van der Linden H.C., Runsink A.P., De Schipper F.A., and Meijer C.J.L.M. (2001) HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br. J. Cancer 85: 398–404.

    Article  PubMed  CAS  Google Scholar 

  13. Hamidi A.E., Liu H., Zhang Y., Hamoudi R., Kocjan G., and Du M.Q. (2002) Archival cervical smears: A versatile resource for molecular investigations. Cytopathology 13: 291–299.

    Article  PubMed  Google Scholar 

  14. van der Graaf Y., Molijn A., Doornewaard H., Quint W., van Doorn L.J., and van den Tweel J. (2002) Human papillomavirus and the long-term risk of cervical neoplasia. Am. J. Epidemiol. 156: 158–164.

    Article  PubMed  Google Scholar 

  15. Gunnell A.S., Tran T.N., Torrang A., Dickman P.W., Sparen P., Palmgren J., and Ylitalo N. (2006) Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol. Biomarkers Prev. 15: 2141–2147.

    Article  PubMed  CAS  Google Scholar 

  16. Burghardt E. (1970) Latest aspects of precancerous lesions in squamous and columnar epithelium of the cervix. Int. J. Gynecol. Obstet. 8: 573–580.

    Google Scholar 

  17. Burghardt E., Pickel H., and Girardi F. Colposcopy Cervical Pathology. eds. (1998), 3rd revised and enlarged edition. Georg Thieme Verlag, Stuttgart.

    Google Scholar 

  18. Boon M.E. and Suurmeijer A.J.H. The Pap Smear. eds. (1993), 2nd edition. Coulomb Press Leyden.

    Google Scholar 

  19. Arbyn M., Herbert A., Schenck U., Nieminen P., Jordan J., McGoogan E., Patnick J., Bergeron C., Baldauf J.J., Klinkhamer P., Bulten J., and Martin-Hirsch P. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 18: 133–139.

    Article  PubMed  CAS  Google Scholar 

  20. BSCC. How to take a cervical smear (3rd edition). 2003. Uxbridge, British Society of Clinical Cytology

    Google Scholar 

  21. NCCLS (1994) Papanicolaou technique; approved guideline. National Comity for Clinical Laboratory Standards, Pensylvania.

    Google Scholar 

  22. Koss L. and Gompel C. Introduction to gynecologic cytopathology with histologic and clinical correlations. Mitchell C.W., eds. (1999), Pradel edn.

    Google Scholar 

  23. Howell L.P., Davis R.L., Belk T.I., Agdigos R., and Lowe J. (1998) The AutoCyte preparation system for gynecologic cytology. Acta Cytol. 42: 171–177.

    Article  PubMed  CAS  Google Scholar 

  24. Hutchinson M.L., Isenstein L.M., Goodman A., Hurley A., Douglas K.L., Mui K.K., Patten F.W., and Zahniser D.J. (1994) Homogeneous sampling accounts for the increased diagnostic accuracy using the thinprep processor. Am. J. Clin. Pathol. 101: 215–219.

    PubMed  CAS  Google Scholar 

  25. Austin R.M. and Ramzy I. (1998) Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. Acta Cytol. 42: 178–184.

    Article  PubMed  CAS  Google Scholar 

  26. Linder J. and Zahniser D. (1997) The ThinPrep Pap test. A review of clinical studies. Acta Cytol. 41: 30–38.

    PubMed  CAS  Google Scholar 

  27. Ferenczy A. and Franco E.L. (1997) Human Papillomavirus DNA testing using liquid-based cytology, in: New Developments in Cervical Cancer Screening and Prevention (Franco, E. L. and Monsonego, J., eds.), Blackwell Science, Cambridge, pp. 343–353.

    Google Scholar 

  28. Sherman M.E., Schiffman M.H., Lorincz A.T., Herrero R., Hutchinson M.L., Bratti C., Zahniser D., Morales J., Hildesheim A., Helgesen K., Kelly D., Alfaro M., Mena F., Balmaceda I., Mango L., and Greenberg M. (1997) Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 81: 89–97.

    Article  PubMed  CAS  Google Scholar 

  29. Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., Raab S., Sherman M.E., Wilbur D., Wright T.C., and Young N. (2002) The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287: 2114–2119.

    Article  PubMed  Google Scholar 

  30. Herbert A., Bergeron C., Wiener H., Schenck U., Klinkhamer P.J., Bulten J., and Arbyn M. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for cervical cytology terminology. Cytopathology 18: 213–219.

    Article  PubMed  CAS  Google Scholar 

  31. Castle P.E., Solomon D., Hildesheim A., Herrero R., Concepcion B.M., Sherman M.E., Rodriguez A.C., Alfaro M., Hutchinson M.L., Terence D.S., Kuypers J., and Schiffman M.A. (2003) Stability of archived liquid-based cervical cytologic specimens. Cancer 99: 89–96.

    Article  PubMed  Google Scholar 

  32. Bergeron C., Cas F., Fagnani F., Didailler-Lambert F., and Poveda J.D. (2006) Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. Acta Cytol. 50: 16–22.

    Article  PubMed  Google Scholar 

  33. Canfell K., Gray W., Snijders P.J., Murray C., Tipper S., Drinkwater K., and Beral V. (2004) Factors predicting successful DNA recovery from archival cervical smear samples. Cytopathology 15: 276–282.

    Article  PubMed  CAS  Google Scholar 

  34. Moberg M., Gustavsson I., and Gyllensten U. (2004) Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int. J. Cancer 112: 854–859.

    Article  PubMed  CAS  Google Scholar 

  35. Tarkowski T.A., Rajeevan M.S., Lee D.R., and Unger E.R. (2001) Improved detection of viral RNA isolated from liquid-based cytology samples. Mol. Diagn. 6: 125–130.

    Article  PubMed  CAS  Google Scholar 

  36. Cuschieri K.S., Beattie G., Hassan S., Robertson K., and Cubie H. (2005) Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J. Virol. Methods 124: 211–215.

    Article  PubMed  CAS  Google Scholar 

  37. Powell N., Smith K., and Fiander A. (2006) Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J. Virol. Methods 137: 58–62.

    Article  PubMed  CAS  Google Scholar 

  38. Boulet G.A.V., Horvath C.A.J., Berghmans S., Moeneclaey L.M., Duys I.S.M., Arbyn M., Depuydt C.E., Vereecken A.J., Sahebali S., and Bogers J.J. (2008) Cervical cytology biobanking: Quality of DNA from archival cervical Pap-stained smears. J. Clin. Pathol. 61(5), 637–641.

    Article  PubMed  CAS  Google Scholar 

  39. Depuydt C., Vereecken A.J., Salembier G.M., Vanbrabant A.S., Boels L.A., van Herck E., Arbyn M., Segers K., and Bogers J.J. (2003) Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br. J. Cancer 88: 560–566.

    Article  PubMed  CAS  Google Scholar 

  40. Horvath C.A., Boulet G., Sahebali S., Depuydt C., Vermeulen T., Vanden Broeck D., Vereecken A., and Bogers J. (2007) Effects of fixation on RNA integrity in a liquid-based cytology setting. J. Clin. Pathol.

    Google Scholar 

  41. Cuschieri K.S., Whitley M.J., and Cubie H.A. (2004) Human papillomavirus type specific DNA and RNA persistence – Implications for cervical disease progression and monitoring. J. Med. Virol. 73: 65–70.

    Article  PubMed  CAS  Google Scholar 

  42. Molden T., Nygard J.F., Kraus I., Karlsen F., Nygard M., Skare G.B., Skomedal H., Thoresen S.O., and Hagmar B. (2005) Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL pap smear. Int. J. Cancer 114: 973–976.

    Article  PubMed  CAS  Google Scholar 

  43. Chuaqui R., Cole K., Cuello M., Silva M., Quintana M.E., and Emmert-Buck M.R. (1999) Analysis of mRNA quality in freshly prepared and archival Papanicolaou samples. Acta Cytol. 43: 831–836.

    Article  PubMed  CAS  Google Scholar 

  44. Liu H., Huang X., Zhang Y., Ye H., El Hamidi A., Kocjan G., Dogan A., Isaacson P.G., and Du M.Q. (2002) Archival fixed histologic and ­cytologic specimens including stained and unstained materials are amenable to RT-PCR. Diagn. Mol. Pathol. 11: 222–227.

    Article  PubMed  Google Scholar 

  45. Iftner T. and Villa L.L. (2003) Chapter 12: Human papillomavirus technologies. J. Natl. Cancer Inst. Monogr. 80–88.

    Google Scholar 

  46. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. (2006) Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24 S3: 78–89.

    Google Scholar 

  47. Cuzick J., Mayrand M.H., Ronco G., Snijders P., and Wardle J. (2006) Chapter 10: New dimensions in cervical cancer screening. Vaccine 24: 90–97.

    Article  Google Scholar 

  48. Arbyn M., Dillner J., Schenck U., Nieminen P., Weiderpass E., Da Silva D. et al. (2007) Chapter 3: Methods for screening and diagnosis, in: European Guidelines for Quality Assurance in Cervical Cancer Screening (Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., Wiener, H. and European Commission, eds.), Office for Official Publications of the European Communities, Luxembourg, pp. 1–69.

    Google Scholar 

  49. Coutlee F., Gravitt P., Kornegay J., Hankins C., Richardson H., Lapointe N., Voyer H., and Franco E. (2002) Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J. Clin. Microbiol. 40: 902–907.

    Article  PubMed  CAS  Google Scholar 

  50. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J.L.M., and Snijders P.J. (1995) The use of general primers GP5 and GP6 elongated at their 3’ end with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76: 1057–1062.

    Article  PubMed  Google Scholar 

  51. Söderlund-Strand A., Carlson J., and Dillner J. (2009) Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomaviruses. J. Clin. Microbiol. 47: 541–546.

    Article  PubMed  Google Scholar 

  52. Kleter B., van Doorn L.J., Schrauwen L., van Krimpen K., Burger M., ter Harmsel B., and Quint W. (1998) Novel short-fragment PCR assey for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153: 1731–1739.

    Article  PubMed  CAS  Google Scholar 

  53. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., Lindeman J., ter Harmsel B., Burger M., and Quint W. (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37: 2508–2517.

    PubMed  CAS  Google Scholar 

  54. Söderlund-Strand A., Dillner J., and Carlson J. (2008) High-throughput genotyping of oncogenic human papillomaviruses with MALDI-TOF mass spectrometry. Clin. Chem. 54: 86–92.

    Article  PubMed  Google Scholar 

  55. Sotlar K., Selinka H.C., Menton M., Kandolf R., and Bultmann B. (1998) Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol. Oncol. 69: 114–121.

    Article  PubMed  CAS  Google Scholar 

  56. Smits H.L., van Gemen B., Schukkink R., Van der Velden J., Tjong A.H., Jebbink M.F., and ter Schegget J. (1995) Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J. Virol. Methods 54: 75–81.

    Article  PubMed  CAS  Google Scholar 

  57. Martin C.M., Astbury K., and O’Leary J.J. (2006) Molecular profiling of cervical neoplasia. Expert. Rev. Mol. Diagn. 6: 217–229.

    Article  PubMed  CAS  Google Scholar 

  58. Keating J.T., Ince T., and Crum C.P. (2001) Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv. Anat. Pathol. 8: 83–92.

    Article  PubMed  CAS  Google Scholar 

  59. zur Hausen H. (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2: 342–350.

    Article  PubMed  CAS  Google Scholar 

  60. IARC. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10. eds. (2005). IARCPress, Lyon.

    Google Scholar 

  61. von Knebel D.M. (2002) New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur. J. Cancer 38: 2229–2242.

    Article  Google Scholar 

  62. Sahebali S., Depuydt C., Boulet G.A., Arbyn M., Moeneclaey L.M., Vereecken A.J., van Marck E.A., and Bogers J.J. (2006) Immunocytochemistry in liquid-based cervical cytology: Analysis of clinical use following a cross-sectional study. Int. J. Cancer 118: 1254–1260.

    Article  PubMed  CAS  Google Scholar 

  63. Wentzensen N., Bergeron C., Cas F., Eschenbach D., Vinokurova S., and von Knebel D.M. (2005) Evaluation of a nuclear score for p16(INK4a)-stained cervical squamous cells in liquid-based cytology samples. Cancer 461–467.

    Google Scholar 

  64. Bergeron C., Wentzensen N., Cas F., and Doeberitz M.V. (2006) The p16INK4a protein: A cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix. Ann. Pathol. 26: 397–402.

    Article  PubMed  Google Scholar 

  65. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., and von Knebel D.M. (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92: 276–284.

    Article  PubMed  CAS  Google Scholar 

  66. Nieh S., Chen S.-F., Chu T.-Y., Lai H.-C., and Fu E. (2003) Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol. Oncol. 91: 201–208.

    Article  PubMed  CAS  Google Scholar 

  67. Wulfkuhle J.D., Liotta L.A., and Petricoin E.F. (2003) Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3: 267–275.

    Article  PubMed  CAS  Google Scholar 

  68. Kuramitsu Y. and Nakamura K. (2006) Proteomic analysis of cancer tissues: Shedding light on carcinogenesis and possible biomarkers. Proteomics 6: 5650–5661.

    Article  PubMed  CAS  Google Scholar 

  69. Yim E.K. and Park J.S. (2006) Role of proteomics in translational research in cervical cancer. Expert. Rev. Proteomics. 3: 21–36.

    Article  PubMed  CAS  Google Scholar 

  70. Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonner J., Curran W.J., Jr., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J., Raghavan D., Reaman G.H., Sawaya R., Schilsky R.L., Schuchter L.M., Sweetenham J.W., Vahdat L.T., and Winn R.J. (2007) Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening – A report from the American Society of Clinical Oncology. J. Clin. Oncol. 25: 146–162.

    Article  PubMed  CAS  Google Scholar 

  71. Sasieni P., Adams J., and Cuzick J. (2003) Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. Br. J. Cancer 89: 88–93.

    Article  PubMed  CAS  Google Scholar 

  72. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., and Meijer C.J. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518–527.

    Article  PubMed  Google Scholar 

  73. Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J.T., and Hakama M. (1996) Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study. BMJ 312: 537–539.

    Article  PubMed  CAS  Google Scholar 

  74. Dillner J., Lehtinen M., Bjorge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R.E., Hallmans G., Paavonen J., Sapp M., Schiller J.T., Hakulinen T., Thoresen S., and Hakama M. (1997) Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive ­cervical cancer. J. Natl. Cancer Inst. 89: 1293–1299.

    Article  PubMed  CAS  Google Scholar 

  75. Laukkanen P., Koskela P., Pukkala E., Dillner J., Laara E., Knekt P., and Lehtinen M. (2003) Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J. Gen. Virol. 84: 2105–2109.

    Article  PubMed  CAS  Google Scholar 

  76. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Moller H., Hakama M., and Parkin D.M. (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol. Biomarkers Prev. 14: 677–686.

    Article  PubMed  Google Scholar 

  77. Arbyn M., Raifu A.O., Autier P., and Ferlay J. (2007) Burden of cervical cancer in Europe: Estimates for 2004. Ann. Oncol. 18: 1708–1715.

    Article  Google Scholar 

  78. Cheung A.N. (2007) Molecular targets in gynaecological cancers. Pathology 39: 26–45.

    Article  PubMed  CAS  Google Scholar 

  79. Dillner J., Arbyn M., and Dillner L. (2007) Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 148: 199–207.

    Article  PubMed  CAS  Google Scholar 

  80. Lehtinen M., Kaasila M., Pasanen K., Patama T., Palmroth J., Laukkanen P., Pukkala E., and Koskela P. (2006) Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int. J. Cancer 119: 2612–2619.

    Article  PubMed  CAS  Google Scholar 

  81. Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J., and Smith P.G. (2006) Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24: 233–241.

    Article  Google Scholar 

  82. Hansson M.G., Dillner J., Bartram C.R., Carlson J.A., and Helgesson G. (2006) Should donors be allowed to give broad consent to future biobank research? Lancet Oncol. 7: 266–269.

    Article  PubMed  Google Scholar 

  83. Hansson M.G. (2005) Building on relationships of trust in biobank research. J. Med. Ethics 31: 415–418.

    Article  PubMed  CAS  Google Scholar 

  84. Helgesson G., Dillner J., Carlsson J., Bartram C.R., and Hansson M.G. (2007) Ethical framework for previously collected biobank samples. Nat. Biotechnol. 25: 973–975.

    Article  PubMed  CAS  Google Scholar 

  85. Arbyn M., Wallyn S., Van Oyen H., Nys H., Dhont J., and Seutin B. (1999) The new privacy law in Belgium: A legal basis for organised cancer screening. Eur. J. Health Law 6: 401–407.

    Article  Google Scholar 

Download references

Acknowledgments

We thank Prof. M.G. Hansson (Centre for Bioethics at Karolinska Institutet and Uppsala University, Uppsala Science Park, SE-75185 Uppsala, Sweden) and Don Chalmers (Faculty of Law School, University of Tasmania, Australia) for the review of subchapter 9 on legal and ethical issues. We are also grateful to Cindy Simoens (Scientific Institute of Public Health, Brussels) for editorial assistance.

Funding was received from the 6th Framework Programme (European Commission, DG Research, Brussels, Belgium) through the CCPRB Network (University of Lund, Malmö, Sweden), the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT-Vlaanderen, refnum 060081), and the Belgian Cancer Foundation.

Author information

Authors and Affiliations

  1. Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium

    Marc Arbyn

  2. Department of Medical Microbiology, University Hospital Malmö, University of Lund, Malmö, Sweden

    Kristin Andersson

  3. Laboratoire Pasteur-Cerba, Cergy Pontoise, Saint Ouen l’Amone, France

    Christine Bergeron

  4. Applied Molecular Biology Research Group (AMBIOR), Laboratory for Cell and Tissue Research, University of Antwerp, Antwerp, Belgium

    John-Paul Bogers

  5. Institute of Pathology, University of Heidelberg, Heidelberg, Germany

    Magnus von Knebel-Doebertitz

  6. Bio Banking and Molecular Resource, Infrastructure of Sweden (BBMRI.se), Karolinska Institutet, Stockholm, Sweden

    Joakim Dillner

Authors
  1. Marc Arbyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristin Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Bergeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John-Paul Bogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Magnus von Knebel-Doebertitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joakim Dillner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Arbyn .

Editor information

Editors and Affiliations

  1. , Bio Banking and Molecular Resource, Karolinska Institutet, Stockholm, 205 02, Sweden

    Joakim Dillner

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Arbyn, M., Andersson, K., Bergeron, C., Bogers, JP., von Knebel-Doebertitz, M., Dillner, J. (2011). Cervical Cytology Biobanks as a Resource for Molecular Epidemiology. In: Dillner, J. (eds) Methods in Biobanking. Methods in Molecular Biology, vol 675. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-423-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-423-0_15

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-58829-995-6

  • Online ISBN: 978-1-59745-423-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation